Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00295906
Other study ID # CDR0000454721
Secondary ID RIH-1050258954A1
Status Recruiting
Phase N/A
First received February 23, 2006
Last updated December 17, 2013
Start date June 2004

Study information

Verified date November 2008
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority Unspecified
Study type Interventional

Clinical Trial Summary

RATIONALE: Computer-based continuing education courses may be effective in improving the skills of primary care doctors to identify skin cancer risk factors, perform skin cancer exams, and counsel patients. They may also improve the skills of primary care doctors to assess and counsel patients on their weight, diet, and physical activity.

PURPOSE: This randomized clinical trial is studying how well computer-based continuing education courses work in improving doctors' ability to perform skin cancer or weight control exams and counseling during routine office visits.


Description:

OBJECTIVES:

Primary

- Compare the efficacy of a continuing education course designed to improve primary care physician performance in examination and counseling of patients about skin cancer vs a continuing education course designed to improve physician assessment of weight management.

- Evaluate physician performance of skin examination during routine patient visits at 12 months after completion of the skin cancer continuing education course.

- Evaluate physician counseling around skin cancer issues.

Secondary

- Evaluate the efficacy of the skin cancer continuing education course in improving physician skin cancer triage skills and in changing physician attitudes and knowledge regarding skin cancer issues.

- Assess improvements in physician assessment of weight, diet, and physical activity.

OUTLINE: This is a randomized, multicenter study. Physicians are stratified according to participating center. Physicians are randomized to 1 of 2 intervention arms.

- Arm I (skin cancer continuing education course): Physicians complete a 1-hour continuing education course on skin cancer. The course is available to the physician as a reference for up to 12 months. Physicians complete an online test at baseline, immediately after the course is completed, and at 1 month and 12 months after course completion to assess their knowledge, attitudes, skill, and practices towards skin examination and skin cancer counseling.

Patients are interviewed by telephone within 1 week after a routine office visit with their physician to assess the physician's skin assessment and skin cancer counseling practices. The interviews are conducted prior to and at 1 month and 12 months after the physician completes the continuing education course.

- Arm II (weight control continuing education course): Physicians complete a 1-hour continuing education course on weight, dietary, and physical activity assessment and counseling. The course is available to the physician as a reference for up to 12 months. Physicians complete an online test at baseline, immediately after the course is completed, and at 1 month and 12 months after course completion to assess their knowledge, attitudes, skill, and practices towards weight, dietary, and physical activity assessment and counseling.

Patients are interviewed by telephone within 1 week after a routine office visit with their physician to assess the physician's weight, dietary, and physical activity assessment and counseling practices. The interviews are conducted prior to and at 1 month and 12 months after the physician completes the continuing education course.

PROJECTED ACCRUAL: A total of 50 physicians and 4,500 patients will be accrued for this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 4550
Est. completion date
Est. primary completion date January 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Primary care physician, meeting all of the following criteria:

- General internist or family physician

- Must devote at least 75% of their time to primary care practice

- At least 1 year in practice

- Must be in a community-based practice with no more than 1 participating physician per practice

- Must not be planning to retire within the next 2 years

- Has a patient population that is predominantly at substantial risk of melanoma and other skin cancers (i.e., adults whose non-sun-exposed skin color is white or tan, but not brown)

- Patient

- Adult who is scheduled for a routine office visit with a study physician

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Study Design

Allocation: Randomized


Intervention

Other:
educational intervention

internet-based intervention


Locations

Country Name City State
United States Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center Columbus Ohio
United States Kimmel Cancer Center at Thomas Jefferson University - Philadelphia Philadelphia Pennsylvania
United States Rhode Island Hospital Comprehensive Cancer Center Providence Rhode Island
United States Scripps-Ranch Family Medicine Clinic at University of California San Diego California
United States University of Kansas School of Medicine - Wichita Wichita Kansas

Sponsors (2)

Lead Sponsor Collaborator
Rhode Island Hospital National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient exit interviews at 12 months No
Secondary Patient exit interviews at 2 months No
See also
  Status Clinical Trial Phase
Completed NCT04062032 - Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma Phase 2
Completed NCT03620019 - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma Phase 2
Active, not recruiting NCT03291002 - Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC Phase 1
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Completed NCT00962845 - Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery Early Phase 1
Completed NCT00324623 - Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma Phase 1
Completed NCT00104845 - Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Phase 1
Completed NCT00096382 - Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00072085 - Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma Phase 2
Completed NCT00089193 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma Phase 2
Completed NCT00072124 - Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma Phase 3
Active, not recruiting NCT00039234 - Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Phase 3
Completed NCT00049010 - Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma N/A
Completed NCT00042783 - Vaccine Therapy in Treating Patients With Stage IV Melanoma Phase 2
Completed NCT00005610 - Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung Phase 2
Completed NCT00006022 - Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer Phase 1
Completed NCT00020358 - Vaccine Therapy in Treating Patients With Melanoma Phase 2
Completed NCT00006385 - Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma Phase 2
Recruiting NCT03767348 - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Phase 2
Withdrawn NCT00006126 - Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery Phase 1